Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Por um escritor misterioso
Descrição
How DUPIXENT® (dupilumab) is Taken: Asthma Dosing
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension
Dupilumab to Treat Type 2 Inflammatory Diseases in Children and
Dupilumab efficacy in children with uncontrolled, moderate-to
Dupixent Reduces Asthma Exacerbations in Younger Children
FDA approves dupilumab for children aged 6 to 11 years with
Full article: A 52-week multicenter retrospective real-world study
P068 DUPILUMAB REDUCES BIOMARKERS OF TYPE 2 INFLAMMATION IN
Advances in understanding and reducing the burden of severe asthma
de
por adulto (o preço varia de acordo com o tamanho do grupo)
